A comparison of the effect of molluscum contagiosum virus MC159 and MC160 proteins on vaccinia virus virulence in intranasal and intradermal infection routes

Sunetra Biswas, Geoffrey L. Smith, Edward J. Roy, Brian Ward and Joanna L. Shisler

Abstract
Molluscum contagiosum virus (MCV) causes persistent, benign skin neoplasm in children and adults. MCV is refractive to growth in standard tissue culture and there is no relevant animal model of infection. Here we investigated whether another poxvirus (vaccinia virus; VACV) could be used to examine MCV immune evasion protein properties in vivo. The MCV MC159L or MC160L genes, which encode NF-κB antagonists, were inserted into an attenuated VACV lacking an NF-κB antagonist (vΔA49), creating vMC159 and vMC160. vMC160 slightly increased vΔA49 virulence in the intranasal and intradermal routes of inoculation. vMC159 infection was less virulent than vΔA49 in both inoculation routes. vMC159-infected ear pinnae did not form lesions, but virus replication still occurred. Thus, the lack of lesions was not due to abortive virus replication. This system provides a new approach to examine MCV immune evasion proteins within the context of a complete and complex immune system.

Molluscum contagiosum virus (MCV) is dermatotropic poxvirus, and is the aetiological agent of molluscum contagiosum (MC) [1]. MCV infections are common and worldwide [2, 3]. MCV infects keratinocytes and infections can persist for months to years [4]. MC neoplasms are small and have little inflammation associated with them [1]. Lesions that spontaneously regress have increased numbers of apoptosing cells, cytotoxic T cells, natural killer cells and type I IFN-expressing plasmacytoid dendritic cells [5]. Thus, it is presumed that one key to MCV persistence lies in MCV modulating the host response. Very little is known about MCV immune evasion strategies as compared to other viruses. This is because MCV is refractive to growth in standard tissue culture. The sequencing of the MCV genome revealed that MCV encodes at least 40 known or predicted immune evasion molecules [6, 7]. Several of these proteins were characterized by studying them independently of MCV infection [4, 8–11]. However, how these MCV immune evasion molecules play a role in viral pathogenesis remains unknown.

To overcome this technical barrier, we chose to deliver MCV immune evasion proteins (MC159 and MC160) to mice during a related poxvirus (VACV) infection. MC159 and MC160 were examined because each protein inhibits NF-κB activation, yet each uses different mechanisms to antagonize the NF-κB activation pathway [12–15]. We chose VACV because it is the best-studied poxvirus [16], and there are several excellent animal models of VACV infection that allow the impact of viral immune evasion molecules on viral pathogenesis to be studied [17–20]. Additionally, we published that MC159 and MC160 inhibit NF-κB and IRF3 activation in murine cell lines [21]. Further, Randall et al. showed that MC159 interacts with the murine NF-κB essential modulator (NEMO) of the IkκB kinase (IKK) complex to inhibit NF-κB activation [15]. We also have unpublished data showing that MC160 induces murine IKK1 degradation, similar to MC160’s effect on human IKK1 [13, 14]. Thus, even though MCV is a human pathogen, it is likely that MCV159 and MC160 interact with some of the known equivalent murine-binding partners involved in immune surveillance.

VACV strain vΔA49 was used as the parental virus (Fig. 1a). vΔA49 lacks A49, which is an NF-κB antagonist [22]. We chose this virus because vΔA49 is moderately
Characterization of vaccinia viruses expressing either MC159 or MC160 genes, each under the control of the VACV p7.5 promoter were inserted into vAA49, a virus construct that deleted nucleotides 113–473 of the A49R gene [22] (Fig. 1a). The expression of MC159L and MC160L was controlled by the VACV p7.5 promoter to ensure MCV gene expression throughout VACV infection. Of course, the expression profile for these MCV genes in VACV may differ from that of its profile during a natural MCV infection. The creation of vMC159 was described previously [12]. The strategy for constructing vMC160 was similar.

To create vMC160, an MC160L gene under the control of the VACV p7.5 promoter was inserted into the pAA49MCS plasmid [12]. pAA49MCS contains a mutated A49R gene lacking nt 113–473 that is flanked by a portion of the A48R and A50R genes [12]. The A48 flank begins at A48R nt 457 and continues through to A49R nt 112 for a 338-bp product [12]. It also possesses multiple cloning sites for insertion of the MC160L gene [12]. To create MC160/pAA49MCS, the MC160L gene was PCR-amplified from MC160/pCI [13] using the forward primer 5'-GGATCTATAATCATGC-GCGAGCCA-3' and the reverse primer 5'-CTAGCTACTGTTTATTC-3' to yield a 1212-bp PCR product. The MC160 nucleotides are underlined. The reverse primer for MC160 was engineered in the Spe I restriction enzyme digestion site (italicized). The p7.5 promoter was PCR-amplified from pUC13/gpt/EGFP [22], yielding a 1212-bp PCR product. The forward primer was 5'-TTTTATCGATTAATAATACAATAATTTATAC-3' and the reverse primer was 5'-CTGCGCATTAGATTATGACTGTCGTCGTC-3', and this yielded a 1212-bp PCR product. The forward primer introduced a ClaI restriction enzyme digestion site (italicized). Next, 50–100 ng of the gel-purified PCR product was joined by SOE PCR and cloned into pAA49MCS that had been digested with ClaI and SpeI and treated with SAP. This plasmid was named MC160/pAA49MCS.

To create vMC160, CV-1 cells were infected with vAA49 and transfected with pMC160, and transient dominant selection was used, as described previously [23]. Recombinant viruses were collected 24 h later, selected in the presence of mycophenolic acid, xanthine and hypoxanthine [23]. This process was repeated three times to isolate vMC160 (m.o.i.=10). Cells were lysed at the indicated times and 15 µg of clarified cellular lysates was subjected to immunoblotting for the presence of MCV (MC159 or MC160) or VACV (E3) proteins or cellular β-actin.
recombinant viruses away from parental viruses. Intermediate EcoGPT<sup>+</sup> viruses were resolved into vMC160 by plaquing on BSC-1 cells in the absence of drugs.

As shown in Fig. 1(b), the genotype of vMC160 was confirmed by using PCR analysis. Note that the 362-bp amplicon from vΔA49-infected cells increased in size to 1692 bp, reflecting insertion of the 883- and 1333-bp MC160<sub>L</sub> inserts. Similarly, there was an 883-bp product when PCR-amplifying the region flanking MC159<sub>L</sub>, as expected. Finally, the 55 kDa MC160 protein expression was detected in infected cells as early as 2 h post-infection (p.i.) and remained detectable at 24 h p.i. using polyclonal antiserum-specific MC160 [24] (Fig. 1c). As previously reported, the 31 kDa MC159 protein was also detected using anti-MC159 antiserum. The VACV E3 protein, an early protein, was detected throughout infection, as predicted [25]. The actin levels were similar in each lane, showing even protein loading.

Intranasal (IN) inoculation allows the examination of VACV virulence; VACV initially infects the lungs and then spreads to the brain and other distal organs [17, 26]. BALB/c mice were inoculated IN with 5×10<sup>6</sup> p.f.u. of a virus as described [27]. The mice were examined daily and we used a five-point scoring system that determines the extent of illness [28, 29]. This was performed as a blinded study to minimize potential bias. We only analysed the planned comparisons of vΔA49 to either vMC159, vMC160 or vΔA49rev, and set P-values of <0.05 (indicated by one asterisk), P<0.01 (as indicated by two asterisks) and P<0.0001 (as indicated by four asterisks) as the criteria for the statistical significance of these and the remaining assays involving mice.

PBS-inoculated mice showed no signs of illness at any time point. vΔA49rev, which is equivalent to wild-type VACV strain WR, triggered clinical signs of illness, similar to previously reported results [22] (Fig. 2a). vΔA49 infection delayed illness onset, and the clinical scores were consistently lower than those for vΔA49rev-infected mice, as noted previously [22]. These differences were statistically significant on days 7–13 p.i. (Fig. 2a). vMC159 infection appeared to cause a milder disease; the clinical scores from vMC159-infected mice were lower than those from vΔA49-infected mice from days 8–12 p.i., and these differences were statistically significant on days 8, 9 and 11–13 p.i. (Fig. 2a). In comparison to vΔA49 infection, mice infected with vMC160 showed increased signs of illness (Fig. 2a). These differences were statistically significant at days 7 and 8 p.i. (Fig. 2a). These data suggest that the MC159<sub>L</sub> gene reduced the virulence of vΔA49, while MC160<sub>L</sub> partially substituted for A49L.

Weight loss is an additional measure of virus virulence for IN inoculations [30]. The same mice as in Fig. 2(a) were also weighed daily, and data were expressed as the percentage of the mean of each individual animal’s weight loss from day 0±SEM [27]. The results are shown in Fig. 2(b). We only analysed the planned comparisons of vΔA49 to either vMC159, vMC160 or vΔA49rev. vΔA49rev infection caused weight loss similar to that reported previously [22]. vΔA49-infected mice lost less weight than vΔA49rev-infected mice, as expected [22], and these differences were statistically significant on days 8–12 p.i. (Fig. 2b). vMC159 caused less weight loss than vΔA49 at days 8–15 p.i., although these differences in weight were not statistically significant. vMC160-infected mice also weighed slightly more than vΔA49-infected mice at days 8–12 p.i., but these differences were not statistically significant. These data suggested that MC159 decreased virus virulence to a greater extent than vMC160 in the IN infection model.

![Fig. 2. The effect of MCV genes on virus virulence using the intranasal (IN) route of infection. Female BALB/c mice (n=5 per group) were inoculated IN with 5×10<sup>6</sup>p.f.u. vΔA49, vΔA49rev, vMC159, or vMC160 or PBS. (a) Clinical signs of illness were monitored daily for 15 days and scored from 0 to 5. Clinical scores were expressed as the mean for each group. One-way analysis of variance (ANOVA) was performed followed by Tukey’s multiple comparison test to determine statistical significance. Asterisks indicate the days on which the clinical signs of illness induced were significantly different between the indicated groups. (**P<0.01, ***P<0.001 or ****P<0.0001). (b) The mice were weighed daily, and data were expressed as the percentage of weight change from day 0. To determine statistically significant differences between weight change during virus infection, two-way ANOVA, followed by Tukey’s multiple comparison test, was performed. Asterisks indicate the days on which weight changes induced by vΔA49 were significantly different from those induced by vΔA49rev (**P<0.05).](image-url)
The intradermal (ID) inoculation of a mouse ear pinna provides an alternative model to examine VACV virulence [19, 31]. In this case, lesion formation and lesion size is used to quantify virulence [18]. One could argue that ID inoculations most closely represent the location of natural, dermatotropic MCV infections. There also are some parallels in the immune responses to ID VACV infections and MCV infections. For example, type I IFN appears to be important in controlling lesion size in VACV-infected ears [32] and lesion resolution during MCV infections [5].

For ID inoculations, C57BL/6 mice were inoculated ID in the left ear dorsal pinna with $10^4$ p.f.u. of each virus as described in [27]. The infected ears were examined daily for the next 18 days for the presence of lesions, and the results are shown in Fig. 3(a). We only analysed the planned comparisons of vΔA49 to either vMC159, vMC160 or vΔA49rev. For all virus infections, no lesions were visually detected for the first six days p.i., a routine observation [27]. Gross lesions were observed in vΔA49rev-infected mice starting on day 7 p.i., and lesion size increased until day 12, before resolving from days 13–18. vΔA49-induced lesion sizes were slightly smaller than those for vΔA49rev at all times examined, and were only statistically significant on days 10 and 11 p.i. vMC160-associated lesions were similar in size to the lesions produced by vΔA49 and slightly larger than vΔA49-induced lesions. When comparing lesions from vMC160- versus vΔA49-infected mice, vMC160 lesions were significantly larger on days 7, 8 and 10 p.i., indicating that MC160 may increase virulence to some extent. Surprisingly, vMC159 inoculation did not produce a lesion at any point in time (Fig. 3a, b).

![Fig. 3. The effect of MCV genes on virus virulence using the intradermal (ID) route of inoculation. C57BL/6 mice (n=5 per group) were infected ID with $10^4$ p.f.u. vΔA49, vΔA49rev, vMC159, or vMC160 in the left ear pinna. Lesion size was expressed as the mean for the group +/− SEM. (a) The sizes of the resulting lesions were measured daily for 18 days. The lesion size was measured by using a 0.01 mm digital caliper. The data are expressed as the means of lesion sizes ± SEM. Statistical significance was determined by two-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison test. The asterisks indicate the days on which the lesion size caused was statistically significantly between indicated groups (*$P<0.05$ or ****$P<0.0001$). (b) Representative images of inoculated ear pinnae at 10 days p.i. vΔA49-infected mice (left panel) or vMC159-infected mice (right panel). (c, d) At the indicated days p.i., ears were collected, homogenized and lysed, and the viral titres of the lysates were determined by plaque assay. Each symbol represents the virus titre from an individual animal, and the mean titre is indicated by a line. The data are expressed as the mean titre of virus (p.f.u.) per gram of tissue (d) and as the total p.f.u. per ear (c). Statistical significance was determined by the Kruskal–Wallis test. The asterisks indicate data points at which the titres of the viruses were statistically significantly different from the others (*$P<0.05$).]
The most striking results observed were those for the ID model of infection, and that there was a complete lack of lesion formation during vMC159 infection. Only two other VACV strains have been reported to not cause lesion formation in skin: vΔA36R and NYVAC [18, 33]. vΔA36R and NYVAC cannot spread from cell to cell efficiently in vitro [18, 33, 34]. It is thought that ΔA36R or NYVAC do not cause lesions because they spread less efficiently to neighbouring cells in vivo, resulting in an abortive infection process.

One question was why vMC159 would cause no lesions. vMC159 and vMC160 each replicated to the same levels as vΔA49 using either one-step or multi-step growth curve assays in mouse embryo fibroblasts (MEFs) (data not shown). Also, vMC159- and vMC160-formed plaques were similar to those for vΔA49 and vA49 in MEFs and BSC40 cellular monolayers (data not shown). Thus, it was unlikely that vMC159 spreads less efficiently for the reasons suspected for vΔA36R and NYVAC. Another possibility was that MC159 and MC160 may not interact with the murine homologues of their binding partners. This is also unlikely because MC159 interacts with murine NEMO [15] and MC160 induces degradation of murine IKK1 (data not shown). Next, the viral titres were quantified at 3, 5 and 11 days p.i. [27]. The maximum VACV titres were detected at day 5 p.i. [19], and we chose these time points to detect virus replication prior to and after maximal replication. vMC160 titres were not examined because the vMC160-induced ear lesions were similar to those for vΔA49 and vΔA49rev.

The data in Fig. 3 are shown as both p.f.u. per ear (panel c) and p.f.u. per gram of tissue (panel d). The starting inoculum was 10^4 p.f.u. in each ear pinna [27]. The data showed that all of the viruses replicated because the virus titres were higher than the initial inoculum (10^5 p.f.u.) on days 3 and 5 p.i. The vMC159 titres were lower than those of the wild-type (vΔA49rev) or parental (vΔA49) viruses at all times tested. The vΔA49 and vΔA49rev titres increased to approximately 1.3 × 10^8 by day 3 p.i. (Fig. 3c). In contrast, the vMC159 titres were 1.2 × 10^5 p.f.u. at day 3 p.i. All of the viruses continued to replicate during the next 48 h because the titres increased between 3 and 5 days p.i. By day 11 p.i., virus replication had waned, as indicated by the decrease in the virus titres. Note that the increase in the virus titres from day 5 to day 11 p.i. implies that there is indeed immune-mediated clearance of virus, but this occurred without accompanying inflammation.

One could argue that no lesions arise because the vMC159 titres are lower than those of vΔA49 in ear pinnae. Indeed, it is unclear what virus titre threshold is needed for lesion formation. Tschark et al. showed that inoculation with as little as 10^2 p.f.u. of VACV induces ear lesion formation [18]. The vMC159 titres greatly exceed that amount at days 3 and 5 p.i. This suggests that vMC159 decouples replication from lesion formation. Interestingly, both ΔA36R and NYVAC elicit protective immune responses (e.g. antibody production) [18, 35]. Thus, it is tempting to ask whether vMC159 also retains its immunogenicity and, if so, whether vMC159 would be useful for the vaccine field.

It is not yet clear how MC159 suppresses lesion formation, and this is a direction for future studies. It is appreciated that VACV lesions are due, in part, to immunopathology because smaller lesions are associated with decreases in the expression of multiple cytokines and chemokines [27, 36]. Thus, MC159 may either directly or indirectly prevent the expression of these host cell proteins to halt pro-inflammatory processes. In this case, the ability of MC159 to inhibit NF-κB and IRF3 activation may be relevant. MC159 inhibits apoptosis, while MC160 does not [24, 37]. Another speculation, then, is that this anti-apoptotic property of MC159 affords virus attenuation, perhaps by allowing virus-infected cells to survive for prolonged time periods. Interestingly, a mutant VACV lacking an apoptosis antagonist (ΔB13R) has an increased lesion size as compared to wild-type VACV [18], showing an instance where inhibition of apoptosis diminishes lesion formation.

This is the first report that examines MCV immune antagonists in the context of an animal infection. MC159 and MC160 are members of the FLIP family of proteins [4]. They each possess tandem death effector domains (DEDs) that share 43% similarity. MC159 and MC160 also share some biological features, including inhibition of NF-κB and IRF3 [4]. Despite their similarity, MC159 and MC160 likely have distinct roles during MCV infection in vivo, as indicated by the data here. VACV itself expresses at least 10 different NF-κB inhibitory proteins [20], indicating that control of this pathway is critical for the survival of VACV in vivo. Perhaps MCV also expresses MC159 and MC160, along with the two other known MCV NF-κB antagonists (MC005, MC132), for similar reasons when confronting a complex, multi-faceted anti-viral immune response [10, 11].

To date, there is no cell culture system or laboratory animal model to study VACV replication and pathogenesis. Researchers have used creative approaches to extrapolate the biological importance of MC159 as an immune evasion molecule. This includes the development of transgenic mouse strains that express MC159 [38, 39] or using murine cytomegalovirus to express MC159 [40]. Our system uses VACV during ID mouse infections, and is perhaps the model that is closest to mimicking MCV infection at this current time. One could argue that the addition of MC159 to vΔA49 resulted in a disease that mimics MC because, like MC, there is little inflammation.

The current study demonstrates the biological effects of two well-characterized MCV immune evasion proteins in a newly created system. MCV encodes at least 40 other known or predicted immune evasion molecules [6, 7]. Thus, studies of MCV immune evasion molecules provide a rich opportunity to identify novel aspects of virus–host interactions during persistent infections. The surrogate system described...
here allows these types of studies to be performed to better understand MCV pathogenesis and persistent virus infections.

Funding information
This work was supported by grants from the University of Illinois Campus Research Board and the National Institutes of Health (All17105). G.L.S. is a Wellcome Trust Principal Research Fellow.

Acknowledgements
The authors thank Dr Ariana Bravo Cruz, Lauren Gates and Melissa Ryerson for advice and review.

Conflicts of interest
The authors declare that there are no conflicts of interest.

Ethical statement
The work described was undertaken with ethical approval from the University of Illinois IACUC.

References


---

Five reasons to publish your next article with a Microbiology Society journal

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.